Top 5 Losers In Healthcare Sector (CTST, PGNX, DCPH…)

The following are some of the healthcare stocks that posted the biggest percentage decline on Monday.

1. CannTrust Holdings Inc. (CTST)

CannTrust is a federally licensed provider of medical cannabis.

Lost 26.81% to close Monday’s (Aug.12) trading at $2.32.

News: CannTrust, which is already in the crosshairs of Health Canada for the growing of cannabis in five unlicensed rooms of its greenhouse facility in Pelham, Ontario and for providing inaccurate information to the regulator, has been pulled up again.

This time the Company’s manufacturing facility in Vaughan, Ontario has been rated non-compliant with certain regulations by Health Canada. The Company has converted five rooms in its manufacturing facility in Vaughan, Ontario from operational areas to storage areas without prior approval of Health Canada.

2. Progenics Pharmaceuticals Inc. (PGNX)

Progenics is a revenue-generating oncology company.

Lost 16.13% to close Monday’s trading at $3.90.

News: No news

Recent event:

On August 9, 2019, the Company reported financial results for the second quarter of 2019 and provided a business update.

The recent second-quarter revenue totaled $10.0 million, up from $3.9 million in the second quarter of 2018.

Clinical Trials & Near-term Catalysts:

— A basket study that will evaluate AZEDRA in patients with NETs that are MIBG-avid, including gastroenteropancreatic neuroendocrine tumors, as well as other NETs, is expected to begin by the end of this year.

Azedra was approved by the FDA last July for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy. Progenics recorded the first commercial sales of Azedra in June 2019.

— A phase III trial of PyL in male patients with biochemical recurrence of prostate cancer, dubbed CONDOR, is underway, with topline data expected by the end of 2019.
— A phase II trial of 1095 in combination with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer is ongoing.
— A phase I trial of PSMA TTC, a PSMA-targeted monoclonal antibody thorium conjugate in the development for the treatment of metastatic castration-resistant prostate cancer, initiated by partner Bayer is ongoing.

3. Deciphera Pharmaceuticals Inc. (DCPH)

Deciphera Pharma is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance.

Lost 15.03% to close Monday’s trading at $19.95.

News: No news

Pipeline & Near-term Catalyst:

The Company’s lead drug candidate is Ripretinib, an orally administered kinase switch control inhibitor being developed for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors, under phase III development.

Also in the pipeline are Rebastinib, which is under two chemo combo trials – one with Paclitaxel and the other with Carboplatin; and DCC-3014, under a phase I study in patients diagnosed with Tenosynovial giant cell tumors.

— Top-line data from a pivotal phase III clinical study of Ripretinib in fourth-line and fourth-line-plus gastrointestinal stromal tumor (GIST) patients, dubbed INVICTUS, due in mid-2019 is awaited.
— Another phase III clinical study comparing Ripretinib to Sunitinib for the treatment of second-line GIST patients who have previously received Imatinib, dubbed INTRIGUE, is underway.
— Data from Part 1 of phase I/II study of Rebastinib with Paclitaxel is expected in the second half of 2019.

4. Autolus Therapeutics Plc (AUTL)

Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies.

Lost 13.59% to close Monday’s trading at $9.79.

News: No news

Recent event:

On August 8, 2019, the Company announced its financial and operational results for the second quarter ended June 30, 2019. Due to manufacturing problems, there is going to be a delay in the initiation and reporting of data of some clinical trials as listed below, according to the Company.

Near-term Catalysts:

— The next-generation version of AUTO2 in multiple myeloma is expected to move into phase I testing in the first half of next year.
— Interim data from phase I trial of AUTO3 in diffuse large B-cell lymphoma (DLBCL) is expected in the fourth quarter of 2019, and the decision for triggering phase II trial initiation is now expected to occur in the second quarter of 2020.
— Initial data from phase I study with AUTO4 in T-cell lymphoma is now expected in the second half of 2020.

5. Harpoon Therapeutics Inc. (HARP)

Harpoon Therapeutics is a clinical-stage an immuno-oncology company.

Lost 12.77% to close Monday’s trading at $10.93.

News: No news

Clinical Trials & Near-term Catalysts:

— The Company’s lead product candidate is HPN424, currently in phase I clinical trial for metastatic castration-resistant prostate cancer. Interim results from this study are expected to be presented at a medical meeting in the first half of 2020.
— A phase I/IIa trial of HPN536, a mesothelin-targeting T cell engager, for ovarian and other mesothelin-expressing solid tumors, is ongoing, with proof of concept data expected to be presented in 2020.
— An IND for HPN217 is expected to be filed by the end of 2019, and a phase I trial is planned for initiation in the first quarter of 2020. HPN217 is a potential treatment for multiple myeloma.
— A phase I trial of HPN328 for the treatment of small-cell lung cancer is expected to be initiated in 2020.

Source: Read Full Article